Kiichiro Ninomiya
0000-0002-2134-2865
Publication & Citation Trends
Most Cited Works
Publications
197 total
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial PDF
Cited by 271
OpenAlex
1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 PDF
Cited by 32
OpenAlex
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers PDF
Cited by 53
OpenAlex
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV PDF
Cited by 150
OpenAlex
The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
Cited by 75
OpenAlex
Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis PDF
Cited by 45
OpenAlex
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
Cited by 37
OpenAlex
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden PDF
Cited by 29
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(124)
Lung Cancer Research Studies
(55)
Cancer Immunotherapy and Biomarkers
(42)
Lung Cancer Diagnosis and Treatment
(28)
HER2/EGFR in Cancer Research
(20)
Frequent Co-Authors
Affiliations
Okayama Shoka University
Novartis (Switzerland)
Okayama University of Science
Okayama University
Tokyo Kasei University